Login
$AEON
$0.15 +$0.01 (7.46%) After hours

$AEON SEC Filings

Filed On Filing
16 Nov 2026 SCHEDULE 13G
16 Nov 2026 10-Q
16 Nov 2026 8-K: Results of Operations and Financial Condition

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

13 Nov 2026 SCHEDULE 13G
10 Nov 2026 SCHEDULE 13D/A
10 Nov 2026 Form 4: Daewoong Co., Ltd, 10% owner

Received 11,236,631 shares by exercise ($1.12K) · Disposed of 3,822 shares (Other Transaction) ($1.12K)

03 Nov 2026 424B3
03 Nov 2026 8-K: Entry into a Material Definitive Agreement

This AMENDMENT TO TWO-YEAR MILESTONE WARRANT TO PURCHASE COMMON STOCK OR PRE-FUNDED WARRANTS (this “Amendment”) is entered into as of November 2, 2026, by and among AEON Biopharma, Inc., a Delaware corporation (the “Company”), and each o...

26 Oct 2026 DEF 14A
23 Oct 2026 8-K: Regulation FD Disclosure

Disrupting a $3.5B neurotoxin market dominated by a single brand for >30 years CORPORATE PRESENTATION / OCTOBER 2026 NYSEAMERICAN: AEON © 2 0 2 6 A E O N B I O P H A R M A

13 Oct 2026 PRE 14A
30 Sep 2026 8-K: Regulation FD Disclosure; Other Events

FDA indicated previously completed ABP-450 head-to-head studies versus BOTOX® may be submitted as supportive evidence; AEON expects to advance the required scientific bridging work

21 Aug 2026 SCHEDULE 13G
21 Aug 2026 Form 4: Lynch Timothy P, 10% owner

Bought 1,150,000 shares ($243K)

21 Aug 2026 Form 3: Lynch Timothy P, 10% owner

Holds 5,350,000 shares of Class A Common Stock

12 Aug 2026 10-Q
12 Aug 2026 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

- Executed a $15.3 million financing with milestone warrants providing potential for an additional $34.0 million in gross proceeds, supporting continued advancement of ABP-450's development program -

03 Aug 2026 8-K: Regulation FD Disclosure; Other Events

Aliso Viejo, Calif., August 3, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company advancing ABP-450 as a biosimilar to BOTOX® (onabotulinumtoxinA) for therapeutic us...

23 Jul 2026 8-K: Other Events

As previously reported, on July 15, 2026, AEON Biopharma, Inc. (the “Company”) completed a public offering (the “Offering”), pursuant to an underwriting agreement (the “Underwriting Agreement”) with Lake Street Capital Markets, LLC, as r...

21 Jul 2026 SCHEDULE 13G

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support